Drug class
TRK/ROS1/ALK tyrosine kinase inhibitor; targeted antineoplastic
Mechanism of action
Inhibits TRKA, TRKB and TRKC, ROS1 and ALK kinase activity, suppressing oncogenic signalling in tumours driven by NTRK gene fusions or ROS1 rearrangements.
General use cases
- Treatment of adults and paediatric patients with solid tumours harbouring an NTRK gene fusion, when disease is metastatic or surgery is likely to cause severe morbidity and there is no satisfactory alternative therapy or progression following treatment
- Treatment of adults with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) under the applicable product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
